Loading...
Loading...
Rexahn Pharmaceuticals, Inc. (NYSE MKT:
RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in Philadelphia, Pennsylvania, on April 18-22, 2015 at the Pennsylvania Convention Center.
The first poster (abstract #2622) entitled, "Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker" on Monday, April 20, 2015, during the "Novel Mechanisms of Drug Pharmacology and Toxicity" poster session from 1:00 pm – 5:00 pm in Poster Section 30.
The second poster (abstract #3577) entitled, "Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)" for RX-5902 will be presented on Tuesday, April 21, 2015, during the "Molecular Targets" poster session from 8:00 am – 12:00 pm in Poster Section 30.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in